BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30060824)

  • 1. Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model.
    Kiyuna T; Murakami T; Tome Y; Igarashi K; Kawaguchi K; Miyake K; Miyake M; Li Y; Nelson SD; Dry SM; Singh AS; Russell TA; Singh SR; Kanaya F; Eilber FC; Hoffman RM
    Tissue Cell; 2018 Aug; 53():30-36. PubMed ID: 30060824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Kiyuna T; Tome Y; Murakami T; Kawaguchi K; Igarashi K; Miyake K; Miyake M; Li Y; Nelson SD; Dry SM; Singh AS; Russell TA; Elliott I; Singh SR; Kanaya F; Eilber FC; Hoffman RM
    BMC Cancer; 2018 Aug; 18(1):840. PubMed ID: 30126369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma.
    Kiyuna T; Tome Y; Murakami T; Zhao M; Miyake K; Igarashi K; Kawaguchi K; Miyake M; Oshiro H; Higuchi T; Li Y; Dry SM; Nelson SD; Russell TA; Eckardt MA; Singh AS; Kanaya F; Eilber FC; Hoffman RM
    J Cell Biochem; 2018 Sep; 119(9):7827-7833. PubMed ID: 29932244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
    Igarashi K; Kawaguchi K; Murakami T; Kiyuna T; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
    J Cell Biochem; 2017 Sep; 118(9):2739-2743. PubMed ID: 28176365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model.
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Singh SR; Tsuchiya H; Hoffman RM
    Tissue Cell; 2019 Jun; 58():107-111. PubMed ID: 31133237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Higuchi T; Yamamoto N; Hayashi K; Kimura H; Miwa S; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2020; 17(4):351-358. PubMed ID: 32576580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model.
    Oshiro H; Tome Y; Kiyuna T; Miyake K; Kawaguchi K; Higuchi T; Miyake M; Zang Z; Razmjooei S; Barangi M; Wangsiricharoen S; Nelson SD; Li Y; Bouvet M; Singh SR; Kanaya F; Hoffman RM
    Tissue Cell; 2019 Jun; 58():17-23. PubMed ID: 31133242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision-oncology nude-mouse model matching the patient with effective therapy.
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
    J Cell Biochem; 2018 Aug; 119(8):6598-6603. PubMed ID: 29737543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model.
    Miyake K; Higuchi T; Oshiro H; Zhang Z; Sugisawa N; Park JH; Razmjooei S; Katsuya Y; Barangi M; Li Y; Nelson SD; Murakami T; Homma Y; Hiroshima Y; Matsuyama R; Bouvet M; Chawla SP; Singh SR; Endo I; Hoffman RM
    Biomed Pharmacother; 2019 Sep; 117():109093. PubMed ID: 31200257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.
    Kiyuna T; Tome Y; Murakami T; Miyake K; Igarashi K; Kawaguchi K; Oshiro H; Higuchi T; Miyake M; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Chawla S; Kanaya F; Eilber FC; Singh SR; Zhao M; Hoffman RM
    Biochem Biophys Res Commun; 2018 Nov; 505(3):733-739. PubMed ID: 30292411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models.
    Kawaguchi K; Igarashi K; Miyake K; Kiyuna T; Miyake M; Singh AS; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Singh SR; Eilber FC; Hoffman RM
    J Drug Target; 2019 Feb; 27(2):211-216. PubMed ID: 30024282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase.
    Igarashi K; Li S; Han Q; Tan Y; Kawaguchi K; Murakami T; Kiyuna T; Miyake K; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
    J Cell Biochem; 2018 Apr; 119(4):3537-3544. PubMed ID: 29143983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients.
    Kawaguchi K; Igarashi K; Kiyuna T; Miyake K; Miyake M; Murakami T; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Singh AS; Unno M; Eilber FC; Hoffman RM
    Cell Cycle; 2018; 17(5):627-633. PubMed ID: 29384032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma.
    Zhang Z; Hu K; Kiyuna T; Miyake K; Kawaguchi K; Igarashi K; Nelson SD; Li Y; Singh SR; Hoffman RM
    Pharmacol Res; 2019 Apr; 142():169-175. PubMed ID: 30807865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
    J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma.
    Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyaki M; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Singh AS; Chmielowski B; Nelson SD; Russell TA; Eckardt MA; Dry SM; Li Y; Singh SR; Chawla SP; Eilber FC; Tsuchiya H; Hoffman RM
    Biochem Biophys Res Commun; 2018 Dec; 506(4):912-917. PubMed ID: 30392912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Methioninase Combined With Tumor-targeting
    Igarashi K; Kawaguchi K; Zhao M; Han Q; Tan Y; Kiyuna T; Miyake K; Higuchi T; Nelson SD; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2515-2523. PubMed ID: 32366396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
    Miyake K; Kiyuna T; Kawaguchi K; Higuchi T; Oshiro H; Zhang Z; Wangsiricharoen S; Razmjooei S; Li Y; Nelson SD; Murakami T; Hiroshima Y; Matsuyama R; Bouvet M; Chawla SP; Singh SR; Endo I; Hoffman RM
    Cancer Chemother Pharmacol; 2019 May; 83(5):809-815. PubMed ID: 30758647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
    Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Murakami T; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM
    Cancer Lett; 2018 Mar; 417():168-173. PubMed ID: 29306021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model.
    Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
    Sci Rep; 2021 Apr; 11(1):8583. PubMed ID: 33883561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.